Manufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery.
Opioid makers face a task that’s partly old, partly new. Besides training docs on their meds' risks, they'd have to include info on rival therapies.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
Pfizer's leukemia drug Mylotarg, pulled off the market in 2010, won backing for a new FDA approval in a Tuesday panel vote.
The pharma industry is challenging a U.K. clampdown for meds projected to cost more than £20 million per year.
Biogen and AbbVie’s MS drug Zinbryta faces new restrictions in Europe at a time when tough payers and new challengers are roiling the field.
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Under pressure from the FDA, Endo will voluntarily pull its opioid painkiller Opana ER from the market.
A controversy over Sanofi's Zika vaccine candidate may spawn pricing limits for all treatments developed with the help of Defense Department funding.
The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.
Two pharma companies are increasing cancer drug prices, and one analyst says it’s evidence drugmakers sometimes raise prices simply “because they can.”